Company: LGNZZ
Filing Date: 2025-04-17
Form Type: 8-K
Source: 0000886163-25-000020
Chunk: 0

Company: LIGAND PHARMACEUTICALS INC
Filing Date: 2025-04-17
Form: 8-K
Item: Item 7.01
Chunk 0
---
Item 7.01 Regulation FD Disclosure.

On April 17, 2025, Ligand Pharmaceuticals Incorporated (“ Ligand”) announced that it and its wholly owned subsidiaries, Pelthos Therapeutics Inc. and LNHC, Inc. (collectively “ Pelthos”) have entered into an Agreement and Plan of Merger (the “ Merger Agreement”) with Channel Therapeutics Corporation (“ Channel”) pursuant to which Pelthos will combine with a wholly-owned subsidiary of Channel (the “ Transaction”). Ligand and Channel issued a joint press release announcing the entry into the Merger Agreement and certain other information regarding the Transaction. A copy of the press release is furnished with this Current Report on Form 8-K (“ Current Report”) as Exhibit 99.1 and is incorporated herein by reference.

In accordance with General Instruction B.2. of Form 8-K, the information in this Item 7.01 of this report, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act”), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.